VRAXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends March 31
Virax Biolabs Group Ltd
Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jul 6, 2026
$1.40−0.05 (-3.45%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Who owns Virax Biolabs's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Armistice Capital, LLC | 823,909 | 9.99% | 13G (passive) | Dec 31, 2025 |
| James Foster | 287,987 | 24.90% | 13G (passive) | Dec 31, 2022 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Nigel William McCracken | Chief Operating Officer, Director | – | – | Mar 20, 2026 |
| Jason Davis | Chief Financial Officer | – | – | Mar 18, 2026 |
| James Alexander Cunliffe Foster | Chief Executive Officer | 287,987 | 49.72% | Mar 18, 2026 |
| Nelson M. Haight | Director | – | – | Mar 31, 2026 |
| Evan Michael Norton | Director | – | – | Mar 18, 2026 |
| Iain David Miller | Director | – | – | Mar 18, 2026 |